De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Atossa Therapeutics Toekomstige groei
Future criteriumcontroles 3/6
De verwachting is dat Atossa Therapeutics de winst en omzet met respectievelijk 71.1% en 72.1% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 70.2% per jaar.
Belangrijke informatie
71.1%
Groei van de winst
70.2%
Groei van de winst per aandeel
| Biotechs winstgroei | 28.8% |
| Inkomstengroei | 72.1% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 11 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth
Jul 01
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Mar 07We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Nov 08Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
Apr 26We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Jan 09Atossa Therapeutics: Still Gets An 'Incomplete' Rating
Oct 11We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely
Sep 25Atossa Therapeutics GAAP EPS of -$0.05
Aug 08Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
May 12A First Assessment On Atossa Therapeutics
Dec 10We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Dec 02Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World
Sep 22Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business
Jul 17Atossa Therapeutics: Hope Springs Eternal
Jun 30Atossa Therapeutics to be included in the Russell 2000, 3000 indexes
Jun 16Atossa reaches a two-year high ahead of data readout for breast cancer therapy
Jun 07Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Apr 02Atossa updates on single-patient study for Endoxifen
Feb 04Atossa halts Endoxifen breast cancer study after positive data
Feb 02Atossa Therapeutics prices ~$25M direct offering, stock -23% PM
Jan 06Atossa Therapeutics prices $14M registered direct offering
Dec 17We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Dec 10
Atossa Therapeutics plummets 38% after it raises $20M in public offering
Dec 09Atossa Therapeutics EPS in-line
Nov 13Safety data on COVID-19 nasal spray fails to lift Atossa, down 6%
Nov 10Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 54 | 1 | -34 | -33 | 3 |
| 12/31/2025 | N/A | -34 | -36 | -27 | 4 |
| 12/31/2024 | N/A | -28 | N/A | -29 | 4 |
| 6/30/2024 | N/A | -26 | -19 | -19 | N/A |
| 3/31/2024 | N/A | -30 | -19 | -19 | N/A |
| 12/31/2023 | N/A | -30 | -21 | -21 | N/A |
| 9/30/2023 | N/A | -30 | -20 | -20 | N/A |
| 6/30/2023 | N/A | -32 | -21 | -21 | N/A |
| 3/31/2023 | N/A | -28 | -23 | -23 | N/A |
| 12/31/2022 | N/A | -27 | -21 | -21 | N/A |
| 9/30/2022 | N/A | -24 | -20 | -20 | N/A |
| 6/30/2022 | N/A | -21 | -18 | -18 | N/A |
| 3/31/2022 | N/A | -22 | -17 | -17 | N/A |
| 12/31/2021 | N/A | -21 | -16 | -16 | N/A |
| 9/30/2021 | N/A | -28 | -16 | -16 | N/A |
| 6/30/2021 | N/A | -26 | -16 | -16 | N/A |
| 3/31/2021 | N/A | -23 | -13 | -13 | N/A |
| 12/31/2020 | N/A | -22 | -12 | -12 | N/A |
| 9/30/2020 | N/A | -13 | -11 | -11 | N/A |
| 6/30/2020 | N/A | -13 | -10 | -10 | N/A |
| 3/31/2020 | N/A | -16 | -10 | -10 | N/A |
| 12/31/2019 | N/A | -17 | -9 | -9 | N/A |
| 9/30/2019 | N/A | -17 | -9 | -9 | N/A |
| 6/30/2019 | N/A | -17 | -9 | -9 | N/A |
| 3/31/2019 | N/A | -25 | -9 | -9 | N/A |
| 12/31/2018 | N/A | -23 | -9 | -9 | N/A |
| 9/30/2018 | N/A | -23 | -8 | -8 | N/A |
| 6/30/2018 | N/A | -22 | -8 | -8 | N/A |
| 3/31/2018 | N/A | -11 | N/A | -7 | N/A |
| 12/31/2017 | N/A | -11 | N/A | -7 | N/A |
| 9/30/2017 | N/A | -11 | N/A | -6 | N/A |
| 6/30/2017 | N/A | -9 | N/A | -4 | N/A |
| 3/31/2017 | N/A | -6 | N/A | -4 | N/A |
| 12/31/2016 | N/A | -6 | N/A | -5 | N/A |
| 9/30/2016 | 0 | -6 | N/A | -8 | N/A |
| 6/30/2016 | 0 | -10 | N/A | -12 | N/A |
| 3/31/2016 | 0 | -12 | N/A | -14 | N/A |
| 12/31/2015 | 0 | -13 | N/A | -14 | N/A |
| 9/30/2015 | 0 | -13 | N/A | -13 | N/A |
| 6/30/2015 | 0 | -13 | N/A | -12 | N/A |
| 3/31/2015 | 0 | -13 | N/A | -11 | N/A |
| 12/31/2014 | 0 | -12 | N/A | -11 | N/A |
| 9/30/2014 | 0 | -12 | N/A | -10 | N/A |
| 6/30/2014 | 0 | -12 | N/A | -10 | N/A |
| 3/31/2014 | 0 | -11 | N/A | -10 | N/A |
| 12/31/2013 | 1 | -11 | N/A | -9 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Er wordt voorspeld dat ATOS de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.5% ).
Winst versus markt: Er wordt verwacht dat ATOS de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.
Hoge groeiwinsten: Er wordt verwacht dat ATOS binnen 3 jaar winstgevend zal worden.
Omzet versus markt: Er wordt verwacht dat ATOS volgend jaar geen omzet zal hebben.
Hoge groei-inkomsten: Er wordt verwacht dat ATOS volgend jaar geen omzet zal hebben.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ATOS naar verwachting over 3 jaar hoog zal zijn